business
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
Key takeaways
- Axo Gen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam Market Beat Thu, May 14, 2026 at 10:06 PM GMT+7 6 min read AXGN Key Points Interested in Axo Gen, Inc.?
- Axo Gen says its core strategy remains focused on developing the peripheral nerve repair market, and CEO Michael Dale reiterated confidence in the company’s Avance platform as a differentiated solution.
- Recent reimbursement wins and the CMS outpatient rate increase should help, but management said the financial impact is still hard to quantify because adoption and contracting take time;
Axo Gen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam Market Beat Thu, May 14, 2026 at 10:06 PM GMT+7 6 min read AXGN Key Points Interested in Axo Gen, Inc.? Here are five stocks we like better.
Axo Gen says its core strategy remains focused on developing the peripheral nerve repair market, and CEO Michael Dale reiterated confidence in the company’s Avance platform as a differentiated solution.
Recent reimbursement wins and the CMS outpatient rate increase should help, but management said the financial impact is still hard to quantify because adoption and contracting take time; Aetna remains the last major payer pending a decision.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop